Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
oral drug delivery
Biotech
Lilly rounds out orforglipron data ahead of obesity filings
With a complete weight loss data set in hand, Lilly is eyeing regulatory filings for orforglipron and thinks approvals could start arriving next year.
Fraiser Kansteiner
Sep 17, 2025 9:00am
Lilly's oral GLP-1 charts 10.5% weight loss in diabetic patients
Aug 26, 2025 6:45am
Viking hits stormy seas as phase 2 oral obesity data sink stock
Aug 19, 2025 9:44am
MindRank reports 10% weight loss on oral GLP-1 drug in phase 2b
Jun 24, 2025 10:06am
AstraZeneca pens $5.3B pact with CSPC to develop oral drugs
Jun 13, 2025 5:56am
Merck links up with Cyprumed in $493M oral peptide deal
Apr 15, 2025 1:11pm
